Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
News for 22nd Century Group, Inc. (Nasdaq: XXII) centers on its role in tobacco harm reduction, regulatory developments, capital structure actions and the commercialization of its VLN® reduced nicotine cigarette platform. Company announcements frequently highlight progress in expanding VLN® and partner VLN® distribution across additional U.S. states and retail chains, including launches with major convenience store operators and authorizations in a large majority of states.
Investors following XXII news will see updates on VLN® regulatory milestones, such as the original FDA Modified Risk Tobacco Product authorization, the filing of the VLN® MRTP renewal application, and the company’s public support for the FDA’s proposed Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products. Releases also discuss clinical research findings related to very low nicotine content cigarettes, including reductions in daily cigarette consumption and increased quit attempts among smokers using 95% reduced nicotine VLN® products.
Another recurring theme in 22nd Century’s news is financial and corporate developments. The company reports on balance sheet changes such as repayment and termination of senior secured debt, settlement of insurance claims related to prior facility incidents, and the use of non-dilutive cash proceeds as growth capital. News items also cover equity and preferred stock financings, at-the-market offering arrangements, and proposals for reverse stock splits and other shareholder approvals under Nasdaq Listing Rules.
In addition, XXII news includes corporate governance and investor relations events, such as participation in investor conferences, quarterly earnings webcasts, and shareholder letters reviewing strategic progress. For readers tracking the intersection of tobacco regulation, reduced nicotine technology and public company capital markets activity, the XXII news feed provides ongoing context on how 22nd Century is executing its harm reduction-focused strategy.
22nd Century Group (Nasdaq: XXII) reported early commercial traction for its FDA-authorized VLN® low nicotine combustible cigarettes. In Q4 2025 the company distributed ~8,800 cartons across ~1,700 new retail outlets, and plans to exceed 5,000 retail points in 2026.
The release cites FDA regulatory developments (Jan 2025 proposed 0.7 mg/g nicotine cap) and reiterates VLN® authorization in Dec 2021 as supporting the company’s market opportunity and distribution expansion.
22nd Century Group (Nasdaq: XXII) preliminarily reported fourth-quarter and full-year 2025 results. Key figures: 2025 revenue $17.6M (down from $24.4M in 2024), 2025 net loss $13.1M, cash $7.1M at year-end and zero long-term debt. Inventory rose to $4.3M.
The company expects audited results on or before March 31, 2026, and will host a conference call. Results are preliminary and subject to year-end audit adjustments.
22nd Century Group (Nasdaq: XXII) issued a 2025 year-in-review letter from CEO Lawrence Firestone highlighting the company’s exit from a multi-year restructuring, relaunch of its VLN® reduced-nicotine cigarette platform, and strengthened balance sheet.
Key facts: VLN® contains ~95% less nicotine, is the only FDA-authorized MRTP combustible cigarette, VLN® relaunched in 2025 and is now in ~2,000 retail locations across 20+ states, and the company eliminated debt and improved liquidity while targeting EBITDA breakeven as higher-margin VLN® sales scale.
22nd Century (Nasdaq: XXII) announced that CEO Larry Firestone and CFO Dan Otto will present at the Needham Growth Conference on January 16, 2026. The management team will be available for virtual one-on-one meetings for investors. Interested parties can register through their Needham representative or contact investor relations at investorrelations@xxiicentury.com to arrange meetings.
22nd Century Group (Nasdaq: XXII) filed a Modified Risk Tobacco Product (MRTP) renewal on Jan 6, 2026 for its VLN® reduced nicotine combustible cigarettes, the only combustible cigarette authorized by the FDA to make low‑nicotine and "helps you smoke less" claims.
Key factual points: VLN® tobacco contains 95% less nicotine; a 2024 marketplace study reported a 40% reduction in daily smoking over 12 weeks; original FDA authorization was issued in Dec 2021 for five years, with renewal due Dec 2026.
22nd Century Group (Nasdaq: XXII) announced that CEO Larry Firestone will present at the Emerging Growth Virtual Investor Conference on Wednesday, December 10, 2025 at 3:55 PM ET.
Investors can register to attend the live webcast and submit questions in advance; an archived webcast will be posted in the Events section of the company's investor relations website if attendees cannot join live.
Background: 22nd Century develops proprietary non‑GMO reduced‑nicotine tobacco (reported as 95% less nicotine vs traditional tobacco) and markets the FDA‑authorized VLN® combustible cigarette.
22nd Century Group (Nasdaq: XXII) announced receipt of $9.5 million in cash proceeds from a settlement with its insurer for business interruption related to the Grass Valley incident (November 2022).
Company leadership said the settlement strengthens the balance sheet and supports a shift from cleanup into a growth phase focused on expanding its core VLN® reduced-nicotine cigarette business. The release reiterates that VLN products contain 95% less nicotine and that the VLN cigarette is the only low-nicotine combustible cigarette authorized by the FDA in the United States.
22nd Century Group (NASDAQ: XXII) announced on Oct 23, 2025 that its VLN® reduced-nicotine cigarettes will begin sales at approximately 140 Circle K locations in Illinois. VLN® products are now authorized for sale in 45 states, with five states pending, and the company unveiled new marketing and consumer-education materials covering its VLN® combustible cigarette lineup.
The company highlights that its proprietary VLN® tobacco contains 95% less nicotine and that VLN® is the first and only combusted cigarette product authorized by the FDA under the agency's low-nicotine framework.
22nd Century Group (Nasdaq: XXII) will report third quarter 2025 results on November 4, 2025. The company will issue a press release at 6:00 AM ET and host a live webcast at 8:00 AM ET with CEO Larry Firestone and CFO Dan Otto reviewing financial results, recent progress, and 2025 plans.
The company highlights its VLN® combustible cigarette containing 95% less nicotine and notes VLN® is the only low‑nicotine combustible cigarette authorized by the FDA in the U.S. Investors can access the live and archived webcast via the company Events page at https://ir.xxiicentury.com/events.
22nd Century Group (Nasdaq: XXII) has submitted public comments supporting the FDA's proposed mandate to reduce nicotine content in cigarettes and certain combusted tobacco products. The company's submission highlights that their Very Low Nicotine Content (VLNC) technology could transform the industry within two years.
According to FDA's model, the proposed rule could prevent 48 million youth and young adults from starting smoking and avert 1.8 million tobacco-related deaths by 2060. The company's VLN® cigarettes, containing 95% less nicotine than traditional cigarettes, are currently the only FDA-authorized low nicotine combustible cigarettes in the U.S.
The initiative has received support from over 75 health care professional organizations, including the American Medical Association and American College of Cardiology, while facing opposition from major tobacco producers.